Luigi Franchi
Plus aucun poste en cours
Profil
Luigi Franchi is the founder of IFM Therapeutics LLC (founded in 2015) and First Wave Bio, Inc. (founded in 2015).
Dr. Franchi is also the founder of Novartis Inflammasome Research, Inc.
Anciens postes connus de Luigi Franchi
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Inflammasome Research, Inc.
 Novartis Inflammasome Research, Inc. Pharmaceuticals: MajorHealth Technology Novartis Inflammasome Research, Inc. operates as a biopharmaceutical company, which engages in the development of a suite of NOD-, LRR- and pyrin domain-containing 3 (NLRP3) antagonists for the treatment of inflammatory diseases. It also develops chemically distinct systemic, gut-directed, and central nervous system (CNS)-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases. The company was founded by Eicke Latz and Luigi Franchi in 2017 and is headquartered in Boston, MA. | Fondateur | - |
First Wave Bio, Inc.
 First Wave Bio, Inc. Miscellaneous Commercial ServicesCommercial Services First Wave Bio, Inc. develops novel therapeutics for the treatment of inflammatory bowel disease. The company was founded by Gary D. Glick, Anthony W. Opipari, Luigi Franchi in 2015 and is headquartered in New York, NY. | Fondateur | - |
IFM Therapeutics LLC
 IFM Therapeutics LLC Pharmaceuticals: MajorHealth Technology IFM Therapeutics LLC engages in the development and transformation of immunotherapy for patients with serious diseases. It focuses on developing small molecule drugs that target the innate immune system. The company was founded by Gary D. Glick, Luigi Franchi, Matthias Geyer, Eicke Latz, and Anthony W. Opipari, Jr. in 2015 and is headquartered in Boston, MA. | Fondateur | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
IFM Therapeutics LLC
IFM Therapeutics LLC Pharmaceuticals: MajorHealth Technology IFM Therapeutics LLC engages in the development and transformation of immunotherapy for patients with serious diseases. It focuses on developing small molecule drugs that target the innate immune system. The company was founded by Gary D. Glick, Luigi Franchi, Matthias Geyer, Eicke Latz, and Anthony W. Opipari, Jr. in 2015 and is headquartered in Boston, MA. | Health Technology |
Novartis Inflammasome Research, Inc.
Novartis Inflammasome Research, Inc. Pharmaceuticals: MajorHealth Technology Novartis Inflammasome Research, Inc. operates as a biopharmaceutical company, which engages in the development of a suite of NOD-, LRR- and pyrin domain-containing 3 (NLRP3) antagonists for the treatment of inflammatory diseases. It also develops chemically distinct systemic, gut-directed, and central nervous system (CNS)-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurological diseases. The company was founded by Eicke Latz and Luigi Franchi in 2017 and is headquartered in Boston, MA. | Health Technology |
First Wave Bio, Inc.
First Wave Bio, Inc. Miscellaneous Commercial ServicesCommercial Services First Wave Bio, Inc. develops novel therapeutics for the treatment of inflammatory bowel disease. The company was founded by Gary D. Glick, Anthony W. Opipari, Luigi Franchi in 2015 and is headquartered in New York, NY. | Commercial Services |
